UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE /	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/718,988	11/21/2003	Bijan Harichian	J6810(C)	2719
201 7590 11/07/2007 UNILEVER INTELLECTUAL PROPERTY GROUP 700 SYLVAN AVENUE, BLDG C2 SOUTH ENGLEWOOD CLIFFS, NJ 07632-3100			EXAMINER .	
			DODSON, SHELLEY A	
			ART UNIT	PAPER NUMBER
BI (ODD) OOD	021110,110 07002 5100	110 07032 3100		
			MAIL DATE	DELIVERY MODE
			11/07/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)			
Office Action Summary		10/718,988	HARICHIAN ET AL.			
		Examiner	Art Unit			
		SHELLEY A. DODSON	1616			
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
WHICH - Extension after SI - If NO pe - Failure t Any repi	RTENED STATUTORY PERIOD FOR REPLY EVER IS LONGER, FROM THE MAILING DA ons of time may be available under the provisions of 37 CFR 1.13 (6) MONTHS from the mailing date of this communication. Fried for reply is specified above, the maximum statutory period we to reply within the set or extended period for reply will, by statute, by received by the Office later than three months after the mailing patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tire fill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed I the mailing date of this communication. ED (35 U.S.C. § 133).			
Status		•				
1)⊠ R	esponsive to communication(s) filed on ELEC	CTION DATED 5/14/2007.				
2a) 🗌 T	This action is FINAL . 2b)⊠ This action is non-final.					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition	n of Claims					
 4) Claim(s) 1-18 is/are pending in the application. 4a) Of the above claim(s) 14-18 is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 1-13 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. 						
Application	1 Papers					
 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. 						
Priority un	der 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s)					
2) Notice of 3) Information	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) tion Disclosure Statement(s) (PTO/SB/08) lo(s)/Mail Date 11/21/2003.	4) Interview Summary Paper No(s)/Mail Do 5) Notice of Informal F 6) Other:	ate			

DETAILED ACTION

Claims 1-18 are pending in this application dated November 21, 2003.

Applicant's claims are directed toward novel skin lightening agents, compositions and methods.

The restriction requirement dated April 12, 2007 is hereby expressly withdrawn.

Restriction Requirement

1. .

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-13, drawn to cosmetic method of skin lightening and composition, classified in class 424, subclass 62.
- II. Claims 14-18, drawn to compounds and process of making the same, classified in class 424, subclass 756.

2.

The inventions are independent or distinct, each from the other because:

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, the different inventions have different modes of operation and effects.

3.

Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the inventions have acquired a separate status in the art in view of their different classification, restriction for examination purposes as indicated is proper.

4.

During a telephone conversation with Edward A. Squillante, Jr. on November 6, 2007 a provisional election was made without traverse to prosecute the invention of Group 1, claims 1-13. Affirmation of this election must be made by applicant in replying to this Office action. Claims 14-18 withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.

5.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Double Patenting

6.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

7.

Claims 1-13 rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-16 of U.S. Patent No. 6,875,425 B2.

Although the conflicting claims are not identical, they are not patentably distinct from each other because both the instant application as well as the referenced patent are claiming skin-lightening composition comprising compounds having the same structural

formula 1. No patentable distinction can be found between the two. In the instant claims when the integer N is 1, the formula 1 is exactly the same.

Information Disclosure Statement

8.

The information disclosure statement (IDS) submitted on November 21, 2007 was noted and the submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the examiner has considered the information disclosure statement.

Telephone Inquiries

9.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHELLEY A. DODSON whose telephone number is (571) 272-0612. The examiner can normally be reached from 7:30 AM to 4:00 PM Monday to Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter, can be reached at 571-272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

Application/Control Number: 10/718,988

Art Unit: 1616

Page 6

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

Shelley A. Dodson Primary Patent Examiner Technology Center 1600